Pre-Market: NANO.PA Nanobiotix (EURONEXT) €33.50 (+16.93%) 10 Mar 2026: momentum

NANO.PA stock jumped 16.93% in pre-market trading to €33.50 on 10 Mar 2026, driven by a heavy read-through in volume at 530,304 shares. The move pushed the day high to €34.00 and lifted the price well above the 50-day average of €20.23. Traders on EURONEXT are watching momentum signals as Nanobiotix S.A. (Healthcare / Biotechnology) posts three- and five-month gains over 80% and 325% respectively. We use price, volume and technical indicators to frame near-term levels and longer-term forecasts for investors following NANO.PA stock.

NANO.PA stock price action and volume

Pre-market activity shows NANO.PA stock at €33.50, up €4.85 from yesterday’s close of €28.65. Volume is 530,304 versus an average of 174,232, giving a relative volume of 3.04, a clear high-volume mover signal. The intraday range sits between €27.35 and €34.00, with the year high at €33.85 and year low at €2.62.

NANO.PA stock fundamentals and valuation

Nanobiotix reports EPS of -1.09 and a trailing PE of -30.73, reflecting its clinical-stage status and negative earnings. Market cap is €1.62B with 48,378,982 shares outstanding. Key ratios: price-to-sales 282.35, price-to-book -23.04, and current ratio 0.63, signaling stretched valuation and tight short-term liquidity.

NANO.PA stock technicals and momentum

Technical indicators show stretched momentum: RSI 85.26 (overbought) and ADX 44.82 indicating a strong uptrend. Bollinger upper band sits at €31.24, with middle at €23.99, implying price moved above the typical volatility band. Short-term support near €28.00 and resistance near €38.00 are relevant for traders managing risk.

Meyka grade and forecast for NANO.PA stock

Meyka AI rates NANO.PA with a score out of 100: 73.82 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12‑month price of €25.46 and a 5‑year target of €66.90. Forecasts are model-based projections and not guarantees.

NANO.PA stock risks, catalysts and sector context

Key near-term catalysts include the earnings announcement scheduled for 31 Mar 2026 and clinical updates for NBTXR3. Risks include continued negative EPS, cash runway pressure, and biotech sector volatility. Healthcare sector averages show more muted YTD performance, so Nanobiotix’s high beta move is sector outlier activity. See recent market comparison and company page for context source and our stock page at Meyka.

Final Thoughts

NANO.PA stock’s €33.50 pre-market print and a 16.93% jump on 10 Mar 2026 mark it as a high-volume mover on EURONEXT today. Short-term technicals show overbought momentum and a likely nearest support at €28.00, while immediate upside faces resistance near €38.00. Fundamental metrics remain tight: EPS -1.09, PE -30.73, and current ratio 0.63, so earnings and cash updates matter. Meyka AI’s forecast model projects a 12‑month price of €25.46, implying an implied downside of -24.00% versus the current price, and a 3‑year target of €46.20, implying a +37.90% upside. These model outputs highlight the split view: short-term momentum vs longer-term model recovery. Traders should size positions for volatility and monitor the earnings date 31 Mar 2026 and clinical news flow. Meyka AI provides this AI-powered market analysis for context; forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.